Press Releases

Email Alerts

Nov 8, 2018

Mr. Matthew Dallas and Mr. Jeffrey Young Appointed to Biostage Board of Directors

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that Mr....
- Photos 1
Nov 8, 2018

Biostage Reports 2018 Third Quarter Financial Results

- Scientific feedback along with new and consistent data continue to validate technology

Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and...
Nov 7, 2018

Ms. Ting Li Appointed to Biostage Board of Directors

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus, and trachea, today announced...
- Photos 1
Nov 6, 2018

Biostage awarded $1.1 million Phase II NIH SBIR Fast-Track grant to develop Cellspan™ Esophageal Implant (CEI) as a novel treatment for pediatric esophageal atresia

- These nondilutive funds support development, testing and IND submission of the Company's pediatric esophageal implant candidate

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced it has...
Nov 2, 2018

Biostage to Host Conference Call to Discuss Third Quarter 2018 Financial Results and Operations

- Conference Call with Live Audio Webcast on Thursday November 8th at 9:30 AM ET -

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it...

Show per page